Overview

Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for the later phase study.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Aspirin